The increased suicidal behaviour in patients with schizophrenia and ADHD suggests the need of further studies on mood regulation and suicidal ideations in these patients.
This study sought to determine whether protein and/or peptide profiles from serum were able to distinguish patients suffering from depression from healthy control subjects and thereby act as biomarker candidates with potential diagnostic value. Serum samples were collected from patients (n = 39) and controls (n = 30). A C8 magnetic bead protocol was used to prepare serum proteins, while a microextraction C18 packed tip was used to isolate serum peptides. Both protein and peptide profiles were recorded by MALDI-MS and the data were exported for further analysis. No protein signals differentiated patients from controls and principle component analysis of the entire peptide profile did not allow for distinct clustering of the two groups. Further analysis of individual peptides however identified three peptide signals whose intensities were significantly different between patients and control subjects. The efficacy of these potential biomarker candidates to identify the patients was therefore studied using a receiver operating characteristic (ROC) curve and the combined use of all three candidates together offered the most specific and sensitive identification of true positive cases of depression.
Whilst disorders with very clear biological causes (such as cancer) exhibit significantly different peptide profiles, psychiatric disorders such as alcohol addiction which are multifactorial show less obvious changes. Despite this the two groups of samples could statistically be distinguished by certain peptides expression levels.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.